I agree that this site is using cookies. You can find further informations here.
X
van Eerden, Ruben A. G
180  results:
Search for persons X
?
1

Reasons for non-feasibility of therapeutic drug monitoring ..:

van der Kleij, Maud B. A. ; Guchelaar, Niels A. D. ; Meertens, Marinda...
British Journal of Cancer.  , 2024
Link: https://doi.org/10.1038/..
 
?
2

Population pharmacokinetics of intraperitoneal irinotecan a..:

Rietveld, Pascale C. S. ; Sassen, Sebastiaan D. T. ; Guchelaar, Niels A. D....
CPT: Pharmacometrics & Systems Pharmacology.  13 (2024)  6 - p. 1006-1016 , 2024
Link: https://doi.org/10.1002/..
 
?
3

Pressurized aerosol versus catheter-based intraperitoneal c..:

Van Den Heuvel, Teun ; Van de Vlasakker, Vincent C.J. ; Rauwerdink, Paulien...
European Journal of Surgical Oncology.  50 (2024)  2 - p. 107714 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5..:

Rietveld, Pascale C.S. ; Guchelaar, Niels A.D. ; van Eerden, Ruben A.G....
Biomedicine & Pharmacotherapy.  176 (2024)  - p. 116820 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Phase I study of intraperitoneal irinotecan combined with p..:

van Eerden, Ruben A G ; de Boer, Nadine L ; van Kooten, Job P...
British Journal of Surgery.  , 2023
Link: https://doi.org/10.1093/..
 
?
6

Intraperitoneal irinotecan combined with systemic chemother..:

van Eerden, Ruben A.G. ; Van De Vlasakker, Vincent ; Guchelaar, Niels A.D....
European Journal of Surgical Oncology.  49 (2023)  2 - p. e200 , 2023
Link: https://doi.org/10.1016/..
 
?
7

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Ca..:

van Eerden, Ruben A. G. ; IJzerman, Nikki S. ; van Meekeren, Milan...
Clinical Pharmacokinetics.  62 (2023)  8 - p. 1129-1139 , 2023
Link: https://doi.org/10.1007/..
 
?
8

Feasibility of therapeutic drug monitoring of sorafenib in ..:

Guchelaar, Niels A.D. ; van Eerden, Ruben A.G. ; Groenland, Stefanie L....
Biomedicine & Pharmacotherapy.  153 (2022)  - p. 113393 , 2022
Link: https://doi.org/10.1016/..
 
?
9

CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implem..:

Mulder, Tessa A. M. ; van Eerden, Ruben A. G. ; de With, Mirjam...
Frontiers in Genetics.  12 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
10

Tissue Type Differences in ABCB1 Expression and Paclitaxel ..:

van Eerden, Ruben A. G. ; van Doorn, Leni ; de Man, Femke M....
Frontiers in Pharmacology.  12 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
11

Docetaxel Skin Exposure and Micronucleation Contributes to ..:

Atrafi, Florence ; van Eerden, Ruben A. G. ; Koolen, Stijn L. W....
Cancers.  13 (2021)  15 - p. 3741 , 2021
Link: https://doi.org/10.3390/..
 
?
12

Feasibility of Extrapolating Randomly Taken Plasma Samples ..:

van Eerden, Ruben A. G. ; Oomen-de Hoop, Esther ; Noordam, Aad..
Pharmaceuticals.  14 (2021)  2 - p. 119 , 2021
Link: https://doi.org/10.3390/..
 
?
13

Effects of Protein and Calorie Restriction on the Metabolis..:

de Man, Femke M. ; van Eerden, Ruben A.G. ; van Doorn, Gerdien M....
Clinical Pharmacology & Therapeutics.  109 (2020)  5 - p. 1304-1313 , 2020
Link: https://doi.org/10.1002/..
 
?
14

Cost-Neutral Optimization of Pazopanib Exposure by Splittin..:

The Dutch Pharmacology Oncology Group (DPOG) ; Groenland, Stefanie L. ; van Eerden, Ruben A. G....
Clinical Pharmacokinetics.  59 (2020)  7 - p. 941-948 , 2020
Link: https://doi.org/10.1007/..
 
?
15

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel ..:

de Man, Femke M. ; van Eerden, Ruben A.G. ; Oomen-de Hoop, Esther...
Cancers.  11 (2019)  6 - p. 826 , 2019
Link: https://doi.org/10.3390/..
 
1-15